Asthma Pharmacotherapy

Asthma pharmacotherapy is organized around two goals: maintaining symptom control and reducing future risk, particularly severe exacerbations, loss of lung function, and medication-related harm. Because asthma is an inflammatory airway disease, current treatment strategies ensure that patients receive inhaled corticosteroid (ICS)-containing therapy rather than relying on bronchodilation alone (GINA, 2025; Wilken & Eades, 2026).

Assess, Adjust, Review

GINA uses a continuous cycle of assessment, treatment adjustment, and review. Before stepping therapy up, confirm the diagnosis when necessary and assess symptom control, exacerbation risk, inhaler technique, adherence, comorbidities, modifiable exposures, medication access, and patient goals. Treatment intensity should then be adjusted and the response reviewed rather than assuming persistent symptoms always require another medication (GINA, 2025).

Adults and Adolescents: Track 1 Preferred Treatment

For adults and adolescents, GINA Track 1 is the preferred strategy because the reliever itself contains an ICS. Low-dose ICS-formoterol is used whenever symptoms occur, linking bronchodilation with anti-inflammatory treatment and reducing severe exacerbation risk compared with SABA-based treatment (GINA, 2025).

Steps 1–2

At Steps 1–2, low-dose ICS-formoterol is taken as needed for symptom relief. This avoids SABA-only exposure in patients with infrequent symptoms while providing corticosteroid whenever the reliever is used.

Steps 3–4

At Steps 3–4, ICS-formoterol is used as both scheduled maintenance therapy and as-needed reliever therapy. This is maintenance-and-reliever therapy (MART). The same formoterol-containing inhaler provides baseline anti-inflammatory treatment and additional doses during worsening symptoms. ICS-LABA inhalers that contain a LABA other than formoterol cannot be used as MART because the reliever component requires a rapid-onset LABA (GINA, 2025).

Step 5

Patients with persistent symptoms or exacerbations despite optimized Step 4 treatment should undergo expert assessment for difficult-to-treat or severe asthma. This includes confirming adherence and inhaler technique, identifying inflammatory phenotype and comorbidities, and considering add-on therapy such as LAMA or an appropriate biologic (GINA, 2025).

Adults and Adolescents: Track 2 Alternative Treatment

Track 2 is an alternative when ICS-formoterol is unavailable or when a patient with stable asthma is doing well on another ICS-containing regimen and prefers to continue it. The reliever is as-needed SABA or, where available and appropriate, an ICS-SABA combination. If a SABA is used at Step 1, a low dose of ICS should be taken whenever the SABA is taken. At higher steps, daily maintenance ICS-containing therapy is combined with the reliever (GINA, 2025).

Before selecting a SABA-reliever regimen, the prescriber should consider whether the patient is likely to take daily controller therapy reliably. Poor adherence can effectively convert Track 2 into unsafe SABA-only treatment.

Children Ages 6–11 Years

Children ages 6–11 years should not receive SABA-only treatment. Even children with infrequent symptoms should receive ICS-containing therapy. At Step 1, low-dose ICS is taken whenever SABA is taken. Step 2 uses daily low-dose ICS. Step 3 options include low-dose ICS-LABA, medium-dose ICS, or very-low-dose ICS-formoterol MART. Step 4 includes medium-dose ICS-LABA or low-dose ICS-formoterol MART, with expert referral when needed. Step 5 requires phenotypic assessment and consideration of higher-intensity or add-on therapy (GINA, 2025).

Inhaled Corticosteroids

ICS therapy is the pharmacologic foundation of asthma treatment. Even low-dose daily ICS substantially reduces severe exacerbations, hospitalization, and asthma-related death compared with SABA-only treatment. ICS also improves symptoms and reduces exercise-induced bronchoconstriction (GINA, 2025).

Local adverse effects include dysphonia and oropharyngeal candidiasis. Technique, use of an appropriate spacer when indicated, and mouth rinsing after administration can reduce local exposure. Higher doses increase systemic corticosteroid exposure, so escalation should follow reassessment of adherence and inhaler technique rather than simply increasing dose in response to any persistent symptom.

LABA and MART

LABAs provide prolonged bronchodilation. In asthma they should be used with ICS rather than as monotherapy. Formoterol is distinct because its rapid onset permits its use as the reliever component in ICS-formoterol anti-inflammatory reliever and MART regimens. MART reduces severe exacerbations compared with conventional maintenance ICS-LABA plus SABA reliever while providing similar symptom control in many patients (GINA, 2025).

Long-Acting Muscarinic Antagonists

LAMA therapy can be added for selected patients whose asthma remains uncontrolled despite optimized ICS-LABA therapy. Tiotropium is available as a separate inhaler for patients age 6 years and older, and some adults may receive single-inhaler ICS/LABA/LAMA combinations. Add-on LAMA produces modest improvement in lung function and a small reduction in severe exacerbations, but limited additional symptom benefit. Before adding a LAMA for exacerbations, GINA recommends ensuring adequate ICS intensity or considering MART (GINA, 2025).

Leukotriene Receptor Antagonists

Leukotriene receptor antagonists, particularly montelukast, are less effective than daily ICS for preventing exacerbations. They may be useful in selected patients as an alternative or add-on, but they should not displace more effective ICS-containing therapy without a specific reason. Montelukast has been associated with serious neuropsychiatric effects, and patients or caregivers should be counseled accordingly (GINA, 2025).

Severe Asthma and Biologic Therapy

Severe asthma should be distinguished from asthma that is uncontrolled because of incorrect diagnosis, poor adherence, poor inhaler technique, untreated comorbidity, ongoing exposure, or inadequate access to therapy. Once these contributors have been addressed, inflammatory phenotype can guide biologic selection.

GINA lists biologic options including anti-IgE therapy for severe allergic asthma; anti-IL-5 or anti-IL-5 receptor therapy for severe eosinophilic asthma; anti-IL-4 receptor alpha therapy for severe eosinophilic or Type 2 asthma and some patients requiring maintenance oral corticosteroids; and anti-TSLP therapy for severe asthma. Eligibility depends on phenotype, local criteria, age, exacerbation history, and payer requirements (GINA, 2025).

Stepping Down Therapy

When asthma has been well controlled for 2–3 months, therapy can be stepped down to identify the lowest effective treatment intensity. Step-down should occur at a clinically stable time, with exacerbation risk assessed and a written action plan in place. GINA suggests reducing ICS dose by approximately 25%–50%, then reassessing after 2–3 months before further reduction. ICS should not be completely stopped in adults or adolescents with asthma (GINA, 2025).

Acute Asthma Exacerbations

An exacerbation requires rapid assessment of severity, bronchodilator treatment, oxygen when hypoxemia is present, and systemic corticosteroids for moderate or severe disease. In adults, GINA uses prednisolone-equivalent dosing of approximately 40–50 mg each morning for 5–7 days. In children, approximately 1–2 mg/kg/day up to 40 mg for 3–5 days is used. Antibiotics are not routine asthma-exacerbation therapy unless a bacterial infection is independently suspected (GINA, 2025).

Patients should leave acute care with controller therapy optimized, inhaler technique checked, a written action plan, and appropriate follow-up. Repeated exacerbations are a signal to reassess maintenance treatment and the modifiable factors contributing to risk.

Written Asthma Action Plans

Every patient should have a written asthma action plan that explains usual treatment, how to recognize worsening asthma, how and when to increase reliever or controller therapy, when oral corticosteroids may be needed, and when urgent medical evaluation is required. Action plans are part of guided self-management rather than an optional education handout (GINA, 2025).

Special Clinical Situations

Pregnancy

Asthma control can change during pregnancy, and GINA recommends monitoring approximately every 4–6 weeks. Pregnant patients should continue ICS-containing therapy because exacerbations are associated with maternal and fetal risk, including preterm delivery and low birth weight. Usual asthma therapy should not be stopped simply because of pregnancy, and exacerbations should be treated promptly to avoid maternal and fetal hypoxia. Bronchial provocation testing should not be performed during pregnancy (GINA, 2025).

Cough-Variant Asthma

Asthma can present with persistent cough as the only respiratory symptom. Cough-variant asthma is characterized by cough with airway hyperresponsiveness, sometimes without routine bronchodilator reversibility. It should be treated with ICS-containing therapy like other asthma phenotypes. Alternative causes of chronic cough, including upper-airway cough syndrome, chronic rhinosinusitis, GERD, ACE-inhibitor therapy, inducible laryngeal obstruction, and eosinophilic bronchitis, should also be considered (GINA, 2025).

Exercise-Induced Bronchoconstriction

Exercise should not routinely be avoided because physical activity has broad health benefits. Regular ICS-containing therapy reduces exercise-induced bronchoconstriction. Patients using GINA Track 1 may use low-dose ICS-formoterol before exercise when needed, while patients using a SABA-based reliever may use their prescribed reliever before exercise. Persistent exercise symptoms should trigger assessment of baseline asthma control and inhaler technique rather than repeated rescue medication alone (GINA, 2025).

Older Adults

Asthma can be underrecognized in older adults, while heart failure, ischemic heart disease, deconditioning, and COPD can mimic or coexist with asthma. Medication and device selection should account for arthritis, vision, cognition, inspiratory flow, treatment complexity, drug interactions, and adverse effects. A history of smoking or biomass exposure should prompt consideration of COPD or coexisting asthma and COPD (GINA, 2025).

Clinical Prescribing Perspective

Asthma prescribing is less about selecting the strongest inhaler and more about matching treatment intensity to risk while ensuring that every regimen includes an anti-inflammatory component. Before escalating therapy, confirm that the patient is actually receiving the intended medication dose through correct technique and reasonable adherence. Persistent exacerbations despite optimized therapy should prompt phenotype-directed assessment rather than repeated unsystematic increases in corticosteroid exposure.

High-Yield Distinctions

  • Adults and adolescents: Track 1 with ICS-formoterol reliever is preferred when available and appropriate.
  • Steps 1–2 in Track 1 use as-needed low-dose ICS-formoterol; Steps 3–4 use MART.
  • Children ages 6–11 should not receive SABA-only treatment.
  • LABA should not be used without ICS in asthma.
  • Montelukast is less effective than ICS for preventing exacerbations and carries neuropsychiatric risk.
  • Add-on LAMA provides modest benefit and should follow optimization of ICS-containing therapy.
  • Biologics are phenotype-directed treatments for severe asthma after modifiable causes of poor control have been addressed.
  • Step down after sustained control, but do not completely discontinue ICS in adults or adolescents.
  • Pregnancy is a reason to maintain good asthma control and continue ICS-containing therapy, not to withdraw it.
  • Exercise-induced symptoms should prompt appropriate reliever use and reassessment of baseline control.

Content last reviewed:

References

Global Initiative for Asthma. (2025). Asthma management and prevention for adults, adolescents and children 6–11 years: A summary guide for healthcare providers. https://ginasthma.org/wp-content/uploads/2025/06/GINA-Summary-Guide-2025-WEB_FINAL-WMS.pdf

Wilken, L. A., & Eades, A. L. (2026). Asthma. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.Pharmacotherapy_Principles_and_…